Pharmacotherapy: Functional status assessment of the health-related quality of life in patients with osteoarthritis treated by Ceresib

The purpose of this study was to assess the functional status of patients who treated symptoms and signs of knee osteoarthritis compared to placebo and psiprossoustona forward-looking, random, double-blind, parallel group design for 12 weeksMulticenter studies were conducted at 71 sites in the United States and Canada1440 patients with active knee osteoarthritis were exposed to flaresPatients were randomly assigned to one of five treatment groups: placebo; Ceresib 50 mg / day, 100 mg / day and 200 mg / day; and psymon 500 mg /day twiceThe osteoarthritis index of Western Ontario and McMaster University was used to measure functional statusresults showed that at the end of the treatment period, the functional status of the patients in the four active treatment groups was significantly better than that of patients receiving a placeboPatients who received 100 mg of ceresib treatment twice a day had a significantly better pain score than those treated with placebo and psoriasis, the results show that Ceresib is better than placebo in improving the functional status of patients with osteoarthritis, comparable to that of psypson